share_log

基石藥業-B：建議修訂現有組織章程大綱及細則以及採納新組織章程大綱及細則

CSTONE PHARMA-B: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION

香港交易所 ·  Apr 15 05:02
Summary by Moomoo AI
基石藥業-B（股份代號：2616）宣布，為了與2023年12月31日起生效的香港聯合交易所有限公司（「聯交所」）上市規則修訂保持一致，並擴大無紙化上市制度，公司董事會提出修訂現有組織章程大綱及細則，並採納新的組織章程大綱及細則。該修訂需得到股東於即將召開的股東週年大會上以特別決議案形式的批准，方能生效。相關修訂的進一步資料將連同股東週年大會通告一同寄發給股東，並將在聯交所及公司網站上公布。本公告由基石藥業董事會主席李偉博士於2024年4月15日發出。
基石藥業-B（股份代號：2616）宣布，為了與2023年12月31日起生效的香港聯合交易所有限公司（「聯交所」）上市規則修訂保持一致，並擴大無紙化上市制度，公司董事會提出修訂現有組織章程大綱及細則，並採納新的組織章程大綱及細則。該修訂需得到股東於即將召開的股東週年大會上以特別決議案形式的批准，方能生效。相關修訂的進一步資料將連同股東週年大會通告一同寄發給股東，並將在聯交所及公司網站上公布。本公告由基石藥業董事會主席李偉博士於2024年4月15日發出。
KEYSTONE PHARMACEUTICAL-B (SHARE CODE: 2616) ANNOUNCES THAT IN ORDER TO COMPLY WITH THE AMENDMENTS TO THE LISTING RULES OF THE HONG KONG UNITED STOCK EXCHANGE LIMITED (THE “EXCHANGE”) EFFECTIVE FROM 31 DECEMBER 2023, AND TO EXTEND THE PAPERLESS LISTING SYSTEM, THE COMPANY'S BOARD OF DIRECTORS HAS PROPOSED AN AMENDMENT TO THE EXISTING STATUTES AND RULES AND ADOPTS New Articles of Association and Terms. The amendment is subject to shareholder approval in the form of a special resolution at the upcoming Annual General Meeting to take effect. Further information on the amendments will be sent to shareholders together with the notice of the Annual General Meeting and will be published on the Exchange and the Company's website. This announcement was made by Dr. Li Wei, Chairman of the Board of Keystone Pharmaceuticals, on 15 April 2024.
KEYSTONE PHARMACEUTICAL-B (SHARE CODE: 2616) ANNOUNCES THAT IN ORDER TO COMPLY WITH THE AMENDMENTS TO THE LISTING RULES OF THE HONG KONG UNITED STOCK EXCHANGE LIMITED (THE “EXCHANGE”) EFFECTIVE FROM 31 DECEMBER 2023, AND TO EXTEND THE PAPERLESS LISTING SYSTEM, THE COMPANY'S BOARD OF DIRECTORS HAS PROPOSED AN AMENDMENT TO THE EXISTING STATUTES AND RULES AND ADOPTS New Articles of Association and Terms. The amendment is subject to shareholder approval in the form of a special resolution at the upcoming Annual General Meeting to take effect. Further information on the amendments will be sent to shareholders together with the notice of the Annual General Meeting and will be published on the Exchange and the Company's website. This announcement was made by Dr. Li Wei, Chairman of the Board of Keystone Pharmaceuticals, on 15 April 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more